Nail Fungus Treatments: Efinaconazole, Tavaborole, Ciclopirox & Terbinafine

Side-by-side treatment pathways

Decision factor	Efinaconazole 10% solution (Jublia)	Tavaborole 5% solution	Ciclopirox 8% nail lacquer	Oral terbinafine 250 mg
Route	Prescription topical solution	Prescription topical solution	Prescription nail lacquer	Prescription oral tablet
Labeled nail scope	Toenail onychomycosis due to T. rubrum or T. mentagrophytes	Toenail onychomycosis due to T. rubrum or T. mentagrophytes	Mild-to-moderate fingernail/toenail onychomycosis without lunula involvement due to T. rubrum, as part of comprehensive management	Fingernail or toenail dermatophyte onychomycosis
Published course	Once daily for 48 weeks	Once daily for 48 weeks	Daily application for up to 48 weeks, with nail-management requirements	Fingernails: daily for 6 weeks; toenails: daily for 12 weeks
Application burden	Cover affected toenail, folds, nail bed, hyponychium and undersurface where accessible	Cover entire affected toenail and under the tip	Daily lacquer; prior coats removed periodically; unattached infected nail is removed as part of management	Daily systemic medication rather than nail-by-nail application
Important practical boundary	Toenail-specific label; topical use only	Toenail-specific label; topical use only	Medical supervision and nail debridement/management are part of the label	Healthy nail still needs months to grow out after fungal control
Safety / monitoring theme	Local application reactions; solution is flammable	Local application reactions	Local irritation; flammable; nail-removal precautions matter, especially with diabetes/neuropathy	Confirm diagnosis; assess for chronic/active liver disease before treatment; systemic adverse effects and drug interactions require clinician review
Catalog status	Reference-only prescription pathway	Reference-only prescription pathway	Reference-only prescription pathway	Reference-only prescription pathway

The percentages in this table are not a potency ranking. Efinaconazole 10%, tavaborole 5%, ciclopirox 8% and oral terbinafine are different drugs, formulations and routes with different labeled treatment programs.

First decision: is it actually nail fungus?

Nail psoriasis, repeated trauma and other nail disorders can look like onychomycosis. The American Academy of Dermatology describes nail clipping, scraping or other sampling as ways clinicians can help confirm fungal disease. The current oral terbinafine label is even more explicit: appropriate nail specimens should be obtained for laboratory testing before treatment.

That is a very different decision standard from buying an OTC athlete’s-foot cream for a typical skin rash.

Topical nail solutions: long course, low systemic exposure

Efinaconazole 10%

The current Jublia label is for toenail onychomycosis caused by Trichophyton rubrum or T. mentagrophytes. It is applied once daily for 48 weeks, covering the nail and adjacent nail structures specified in the label.

The long course is part of the treatment burden. A topical route may be useful in selected patients, but it still requires consistent application across most of a year.

Tavaborole 5%

Tavaborole is also labeled for toenail onychomycosis caused by T. rubrum or T. mentagrophytes and is applied once daily for 48 weeks. The label directs coverage of the entire toenail surface and under the tip of each treated nail.

Again, 5% versus 10% should not be interpreted as “half as strong”; these are different active ingredients.

Ciclopirox lacquer has a narrower management context

The current ciclopirox 8% nail-lacquer label describes use for mild-to-moderate onychomycosis without lunula involvement in immunocompetent patients and places it inside a comprehensive management program. The label includes removal of unattached infected nail by a qualified healthcare professional as frequently as monthly, alongside daily lacquer application for up to 48 weeks.

That makes ciclopirox more than “paint this on once a day.” Nail preparation and ongoing management are part of the labeled pathway.

Oral terbinafine: shorter course, more systemic considerations

The current terbinafine tablet label covers dermatophyte onychomycosis of fingernails and toenails. It specifies 250 mg once daily for 6 weeks for fingernails and 12 weeks for toenails.

The label also requires a different safety conversation from topical therapy. Appropriate nail testing should confirm the diagnosis, and patients should be evaluated for chronic or active liver disease before treatment. Chronic or active liver disease is a contraindication.

Even after successful treatment, the nail does not instantly look normal: the label notes that optimal clinical appearance follows later as healthy nail grows out.

Why OTC athlete’s-foot terbinafine cream is not in this table

The AAD explicitly distinguishes OTC terbinafine skin cream from nail treatment: the skin cream can treat fungal skin infections but does not adequately penetrate the nail to treat onychomycosis.

Athlete’s-foot products therefore remain separate from nail-fungus treatment pathways even when the word “terbinafine” appears in both contexts.

Questions worth taking to a clinician

Has fungal infection been confirmed, or could this be psoriasis, trauma or another nail disorder?
How many nails are involved, and how much of each nail is affected?
Is the matrix/lunula involved?
Would the long daily topical course be realistic for me?
Do my liver history, medications, pregnancy status, diabetes, circulation or neuropathy change the safest option?
What improvement should I expect during treatment versus only after healthy nail has grown out?

For the broader disease pathway, see Toenail & Nail Fungus.